Login

Switch On Your HIV Smarts.

AIDS 2012 Recap: Complera Switch Study

, by San Francisco AIDS Foundation

The simplified drug regimen Complera, which combines three antiretroviral drugs in a single pill taken once a day, continues to perform well in studies a year after it came on the market.

In the SPIRIT study, reported at the 19th International AIDS Conference at the end of July, switching from a protease inhibitor–based HIV treatment regimen to Complera was not only safe but also helped reduce levels of lipids—fats in the blood—and lowered heart disease risk. See the study results for yourself over at HIVandHepatitis.com.

AIDS 2012: Switching from Protease Inhibitor to Complera Maintains Viral Suppression, Lowers Lipids

By Liz Highleyman

People who switched to the all-in-one Complera (rilpivirine/tenofovir/emtricitabine) combination pill from a boosted protease inhibitor continued to have undetectable viral load and on average had improved lipid profiles associated with lower cardiovascular risk, according to study findings presented at the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC….

Click here to read the full article.

Comments

Comments are closed.

[contact-form-7 id="10015"]
[contact-form-7 404 "Not Found"]